Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Company Overview

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.04 to $0.84
• 52-Week Range: N/A
• Volume: 720,000 shs
• Average Volume: 682,655 shs
• Market Capitalization: $956,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMPL Stock Analysis - Frequently Asked Questions

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) posted its earnings results on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.42. The company earned $0.09 million during the quarter.
Read the conference call transcript.

When did Impel Pharmaceuticals IPO?

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

What other stocks do shareholders of Impel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMPL
• CIK: 1445499
• Web: www.Impelnp.com
• Phone: 206-568-1466
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-106,310,000.00
• Net Margins: -353.93%
• Pretax Margin: -353.93%
• Return on Equity: N/A
• Return on Assets: -127.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: $20.99 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.86) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 23,900,000
• Free Float: 22,418,000
• Market Cap: $956,000.00
• Optionable: Not Optionable
• Beta: 1.17